Please ensure Javascript is enabled for purposes of website accessibility

Why Agile Therapeutics Stock Is Falling Today

By Brian Feroldi - Updated Feb 21, 2020 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares drop after the company releases the pricing details of a recently announced capital raise.

What happened

After sharing the pricing information of a just-announced common stock offering, Agile Therapeutics (AGRX -4.83%), a clinical-stage biopharma focused on women's health, saw its stock fall 14% as of 3:22 p.m. EST on Friday.

So what

Agile announced on Thursday that it wanted to raise capital from a common stock offering. The company released the pricing details of the proposed offering today.

Agile stated that it is selling 15 million shares of stock at $3 per share. The underwriters of the deal are also being granted a 30-day option to purchase up to 2.25 million additional shares.

The problem is that Agile's closing price on Thursday was $3.58, which suggests that the company had to substantially discount the stock in order to attract enough demand from investors. 

Businessman with no money in pockets

Image source: Getty Images.

The deal is expected to raise about $45 million before subtracting fees.

Given the weak pricing details, it's not hard to figure out why shares are taking a step back today. 

Now what

Agile had previously told investors that its cash balance would only last until the end of 2020, so it's not surprising to see the company raise capital now. What's more, the company plans on initiating distribution to wholesalers for its recently approved birth-control patch Twirla in the fourth quarter, so its capital needs are likely to grow from here. 

2020 should be an exciting year for Agile's investors, but there's no guarantee that the demand for Twirla will be as strong as the company needs it to be. For that reason, my plan is to approach this biotechnology stock with a wait-and-see mindset. 

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agile Therapeutics, Inc. Stock Quote
Agile Therapeutics, Inc.
$0.54 (-4.83%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.